

5.21.203

---

|                    |                       |                              |                |
|--------------------|-----------------------|------------------------------|----------------|
| <b>Section:</b>    | Prescription Drugs    | <b>Effective Date:</b>       | July 1, 2026   |
| <b>Subsection:</b> | Antineoplastic Agents | <b>Original Policy Date:</b> | April 14, 2023 |
| <b>Subject:</b>    | Zynyz                 | <b>Page:</b>                 | 1 of 5         |

---

**Last Review Date:** June 11, 2026

---

## Zynyz

### Description

Zynyz (retifanlimab-dlwr)

---

### Background

Zynyz (retifanlimab-dlwr) is a programmed death receptor-1 (PD-1) blocking antibody. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Zynyz binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD-L2, and potentiates T-cell activity (1).

### Regulatory Status

FDA-approved indications: Zynyz is a programmed death receptor-1 (PD-1) blocking antibody indicated: (1)

- Squamous Cell Carcinoma of the Anal Canal (SCAC)
  - in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.
  - as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
- Merkel Cell Carcinoma (MCC)
  - for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.

---

|                    |                       |                              |                |
|--------------------|-----------------------|------------------------------|----------------|
| <b>Section:</b>    | Prescription Drugs    | <b>Effective Date:</b>       | July 1, 2026   |
| <b>Subsection:</b> | Antineoplastic Agents | <b>Original Policy Date:</b> | April 14, 2023 |
| <b>Subject:</b>    | Zynyz                 | <b>Page:</b>                 | 2 of 5         |

---

Zynyz contains warnings for the following: immune-mediated adverse reactions, infusion-related reactions, and complications of allogenic hematopoietic stem cell transplantation (HSCT) (1).

Zynyz can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should be advised to use effective contraception during treatment with Zynyz and for 4 months after the last dose (1).

The safety and effectiveness of Zynyz have not been established in pediatric patients less than 18 years of age (1).

---

#### Related Policies

Keytruda, Loqtorzi, Opdivo

#### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Zynyz may be considered **medically necessary** if the conditions indicated below are met.

Zynyz may be considered **investigational** for all other indications.

### Prior-Approval Requirements

**Age** 18 years of age or older

#### Diagnoses

Patient must have **ONE** of the following:

1. Inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC)
  - a. Used in combination with carboplatin and paclitaxel for first-line treatment
2. Locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC)
  - a. Used as a single agent
  - b. Disease progression on or intolerance to platinum-based chemotherapy

---

|                    |                       |                              |                |
|--------------------|-----------------------|------------------------------|----------------|
| <b>Section:</b>    | Prescription Drugs    | <b>Effective Date:</b>       | July 1, 2026   |
| <b>Subsection:</b> | Antineoplastic Agents | <b>Original Policy Date:</b> | April 14, 2023 |
| <b>Subject:</b>    | Zynyz                 | <b>Page:</b>                 | 3 of 5         |

---

3. Metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)

**AND ALL** of the following:

- a. Prescriber agrees to discontinue treatment for any immune-mediated adverse reaction (e.g., encephalitis, nephritis, rash, decreased renal function, and endocrinopathies) or disease progression
- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Zynyz and for 4 months after the last dose

---

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

### Diagnoses

Patient must have **ONE** of the following:

1. Locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC)
2. Metastatic or recurrent locally advanced Merkel cell carcinoma (MCC)

**AND ALL** of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to discontinue treatment for any immune-mediated adverse reaction (e.g., encephalitis, nephritis, rash, decreased renal function, and endocrinopathies) or disease progression
- c. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Zynyz and for 4 months after the last dose

## Policy Guidelines

### Pre - PA Allowance

None

### Prior - Approval Limits

**Quantity** 4 vials every 84 days

|                    |                       |                              |                |
|--------------------|-----------------------|------------------------------|----------------|
| <b>Section:</b>    | Prescription Drugs    | <b>Effective Date:</b>       | July 1, 2026   |
| <b>Subsection:</b> | Antineoplastic Agents | <b>Original Policy Date:</b> | April 14, 2023 |
| <b>Subject:</b>    | Zynyz                 | <b>Page:</b>                 | 4 of 5         |

**Duration** 12 months

## Prior – Approval *Renewal* Limits

**Quantity** 4 vials every 84 days

**Duration** 12 months\*

\*One renewal **ONLY**

\*\***NO** renewal for inoperable locally recurrent or metastatic SCAC

## Rationale

### Summary

Zynyz is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of adult patients with squamous cell carcinoma of the anal canal (SCAC) or Merkel cell carcinoma (MCC). Patients taking Zynyz should be monitored for immune-mediated adverse reactions. The safety and effectiveness of Zynyz have not been established in pediatric patients less than 18 years of age (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Zynyz while maintaining optimal therapeutic outcomes.

### References

1. Zynyz [package insert]. Wilmington, DE: Incyte Corporation; March 2026.
2. NCCN Drugs & Biologics Compendium® Retifanlimab-dlwr 2026. National Comprehensive Cancer Network, Inc. Accessed on May 12, 2026.

## Policy History

| Date           | Action                                                                               |
|----------------|--------------------------------------------------------------------------------------|
| April 2023     | Addition to PA                                                                       |
| September 2023 | Annual review and reference update                                                   |
| March 2024     | Annual review and reference update                                                   |
| September 2024 | Annual review and reference update                                                   |
| December 2024  | Annual review and reference update                                                   |
| March 2025     | Annual review and reference update                                                   |
| June 2025      | Annual review and reference update                                                   |
| July 2025      | Per PI update, added indications of squamous cell carcinoma of the anal canal (SCAC) |

---

|                    |                       |                              |                |
|--------------------|-----------------------|------------------------------|----------------|
| <b>Section:</b>    | Prescription Drugs    | <b>Effective Date:</b>       | July 1, 2026   |
| <b>Subsection:</b> | Antineoplastic Agents | <b>Original Policy Date:</b> | April 14, 2023 |
| <b>Subject:</b>    | Zynyz                 | <b>Page:</b>                 | 5 of 5         |

---

|                |                                                                                 |
|----------------|---------------------------------------------------------------------------------|
| September 2025 | Annual review and reference update                                              |
| March 2026     | Annual review and reference update                                              |
| April 2026     | Per PI update, increased quantity limit to allow for 375mg dosing every 3 weeks |
| June 2026      | Annual review and reference update                                              |

**Keywords**

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 11, 2026 and is effective on July 1, 2026.**